Cargando…
Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
The SCHOLAR-1 international retrospective study highlighted poor clinical outcomes and survival among patients with refractory large B-cell lymphoma (LBCL) treated with conventional chemotherapy. Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therap...
Autores principales: | Neelapu, Sattva S., Locke, Frederick L., Bartlett, Nancy L., Lekakis, Lazaros J., Reagan, Patrick M., Miklos, David B., Jacobson, Caron A., Braunschweig, Ira, Oluwole, Olalekan O., Siddiqi, Tanya, Lin, Yi, Crump, Michael, Kuruvilla, John, Van Den Neste, Eric, Farooq, Umar, Navale, Lynn, DePuy, Venita, Kim, Jenny J., Gisselbrecht, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945634/ https://www.ncbi.nlm.nih.gov/pubmed/34478487 http://dx.doi.org/10.1182/bloodadvances.2020003848 |
Ejemplares similares
-
A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022) -
Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
por: Hamadani, Mehdi, et al.
Publicado: (2022) -
SIRPα(+) macrophages are increased in patients with FL who progress or relapse after frontline lenalidomide and rituximab
por: Marques-Piubelli, Mario L., et al.
Publicado: (2022) -
Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma
por: Cherng, Hua-Jay J., et al.
Publicado: (2022) -
A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL
por: Cherng, Hua-Jay J., et al.
Publicado: (2022)